Literature DB >> 22264668

French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy.

Yann Neuzillet1, Kurt G Naber, Giancarlo Schito, Laura Gualco, Henry Botto.   

Abstract

OBJECTIVE: Uncomplicated cystitis is one of the most frequent community infections. We report the French results of the international ARESC study on the clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens. PATIENT AND METHODS: Female patients between 18 and 65 years of age, with symptoms of uncomplicated cystitis, were investigated clinically with urinalysis and urine culture. Uropathogens were identified and their susceptibility was tested with nine antimicrobials.
RESULTS: Four thousand and four hundred patients were included, 871 in France, forming the largest national cohort. Urine culture was positive (cfu≥10(4)/ml) in 550 (63.1%); 533 (96.9%) presented with a single bacterium infection. 488 uropathogens, collected from 479 patients, were analyzed. The most frequent were: Escherichia coli (83.8%), Staphylococcus saprophyticus (4.3%), Proteus mirabilis (3.1%), enterococci (1.2%), and Klebsiella pneumoniae (1.0%). E. coli was highly susceptible to fosfomycin (99.0%) (97.1%), nitrofurantoin (97.3%), and ciprofloxacin (98.3%). The lowest susceptibility rates were found for ampicillin (60.9%) and cotrimoxazole (87.8%). Fosfomycin (97.8%), ciprofloxacin (98.3%), and nitrofurantoin (91.5%) had the highest susceptibility rate. The lowest susceptibility rates were observed with ampicillin (61.4%) and cotrimoxazole (86.5%).
CONCLUSIONS: Fosfomycin, pivmecillinam (not available in France), and nitrofurantoin have preserved their in vitro activity and are suitable for empiric therapy. Cotrimoxazole (trimethoprim+sulfamethoxazole) and fluoroquinolones are not usually recommended as first intention drugs for the empiric therapy of uncomplicated cystitis, because of increasing resistance rates.
Copyright © 2012. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264668     DOI: 10.1016/j.medmal.2011.07.005

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  13 in total

1.  Quantification of bacterial uropathogens in preclinical samples using real-time PCR assays.

Authors:  Janet L Enderle; Aaron L Miller; Richard B Pyles
Journal:  Curr Microbiol       Date:  2013-10-10       Impact factor: 2.188

Review 2.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

3.  In vitro comparison of nitrofurazone- and silver alloy-coated foley catheters for contact-dependent and diffusible inhibition of urinary tract infection-associated microorganisms.

Authors:  James R Johnson; Brian Johnston; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

4.  Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France.

Authors:  A Malmartel; C Ghasarossian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-06       Impact factor: 3.267

5.  Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series.

Authors:  Manuel Etienne; Emmanuel Lefebvre; Noëlle Frebourg; Hélène Hamel; Martine Pestel-Caron; François Caron
Journal:  BMC Infect Dis       Date:  2014-03-11       Impact factor: 3.090

6.  Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.

Authors:  Fardod O'Kelly; Siobhan Kavanagh; Rustom Manecksha; John Thornhill; Jérôme P Fennell
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

7.  Antibiotic prescriptions and risk factors for antimicrobial resistance in patients hospitalized with urinary tract infection: a matched case-control study using the French health insurance database (SNDS).

Authors:  Marion Opatowski; Christian Brun-Buisson; Mehdi Touat; Jérôme Salomon; Didier Guillemot; Philippe Tuppin; Laurence Watier
Journal:  BMC Infect Dis       Date:  2021-06-14       Impact factor: 3.090

8.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

Review 9.  Uncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic Aspects.

Authors:  Bernd Wiedemann; Anke Heisig; Peter Heisig
Journal:  Antibiotics (Basel)       Date:  2014-07-22

10.  Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and Comparison with 2000 and 2008.

Authors:  Gunnar Kahlmeter; Jenny Åhman; Erika Matuschek
Journal:  Infect Dis Ther       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.